For three decades, biopharma has operated on a simple premise: therapies are expensive because they are hard to make. Scarcity of successful drugs, not demand, has kept prices high. That premise is weakening – from three directions at once.
On the supply side, artificial intelligence is reaching every stage of drug development, raising output while lowering cost. McKinsey estimates generative AI could unlock $60–110 billion in annual value across pharma and medtech. Discovery is where it shows most: work that once took three to five years is compressing into months. Insilico Medicine’s INS018_055, the first drug candidate with an AI-designed molecule, went from concept to clinic in roughly eighteen months at about six million dollars, and reported significant Phase IIa results in February 2026. AI is also cutting trial timelines 30 to 50 percent and manufacturing costs alongside them.
At the same time, demand is flattening. Per the UN’s 2024 World Population Prospects, population has already peaked in sixty-three countries, including China, Japan, and Germany. Even the United States – roughly 53 percent of the global prescription drug market – is projected to grow under 10 percent through 2100, peaking near 370 million around 2080, and is aging quickly.
Pricing pressure is already visible. Under the Inflation Reduction Act, Medicare negotiated its first drug prices in 2024, effective January 2026, with discounts of 38 to 79 percent off 2023 list prices. Meanwhile AI is not just making existing drugs cheaper but widening what biopharma can build at all – from cell and gene therapies to mRNA platforms. More categories of therapy chasing a flat or shrinking patient base is the textbook setup for oversupply.
None of this means prices collapse next year. But the direction of travel is clear: an industry built on scarcity is watching it erode from the supply side, just as its largest markets shrink and government negotiation applies pressure from a third direction. The companies that prevail will build for abundance rather than scarcity – using AI-accelerated supply to create markets that do not yet exist: new indications, new modalities, new geographies, and new ways of reaching underserved patients. The question is not whether biopharma will feel this pressure, but which companies will act as though the change is already here.
Read the full whitepaper, including all supporting data and charts, in the document below.
